{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:46:22Z","timestamp":1793339182408,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000196","name":"Canada Foundation for Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005247","name":"University of British Columbia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005247","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008593","name":"European Respiratory Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012285","name":"BC Children's Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012285","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Forschung, Technologie und Raumfahrt","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals Incorporated","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001465","name":"American Thoracic Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001465","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jcf.2026.05.014","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T04:10:02Z","timestamp":1781842202000},"page":"778-785","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in children \u22652 years with cystic fibrosis: 96-week interim results from a phase 3 open-label extension study"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6785-5076","authenticated-orcid":false,"given":"Jennifer L.","family":"Goralski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6447-7957","authenticated-orcid":false,"given":"Cori","family":"Daines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3789-1241","authenticated-orcid":false,"given":"Jessica E.","family":"Pittman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4955-8876","authenticated-orcid":false,"given":"Jonathan H.","family":"Rayment","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6129-9075","authenticated-orcid":false,"given":"Philip","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Thursfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Stehling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Ratjen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Ahluwalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengdi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8448-7453","authenticated-orcid":false,"given":"Tanya G.","family":"Weinstock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4057-2199","authenticated-orcid":false,"given":"Marcus A.","family":"Mall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Goralski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Milla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Pittman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvin","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Chmiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Sawicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordana","family":"Hoppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cori","family":"Daines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Ratjen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Rayment","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"McColley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Mall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Stehling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Thursfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Wainwright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Clements","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jcf.2026.05.014_bib0001","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41572-024-00538-6","volume":"10","author":"Mall","year":"2024","journal-title":"Cyst Fibros Nat Rev Dis Primer"},{"issue":"44","key":"10.1016\/j.jcf.2026.05.014_bib0002","doi-asserted-by":"crossref","first-page":"18825","DOI":"10.1073\/pnas.0904709106","article-title":"Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770","volume":"106","author":"Van Goor","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.jcf.2026.05.014_bib0003","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S2213-2600(12)70057-7","article-title":"A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect","volume":"1","author":"Boyle","year":"2013","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.jcf.2026.05.014_bib0004","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1164\/rccm.201011-1892OC","article-title":"Infection, inflammation, and lung function decline in infants with cystic fibrosis","volume":"184","author":"Pillarisetti","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2026.05.014_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1753466618820186","article-title":"Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor\/ivacaftor","volume":"13","author":"Rubin","year":"2019","journal-title":"Ther Adv Respir Dis"},{"issue":"4 Pt 1","key":"10.1016\/j.jcf.2026.05.014_bib0006","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0022-3476(05)82478-3","article-title":"Pancreatic insufficiency, growth, and nutrition in infants identified by newborn screening as having cystic fibrosis","volume":"120","author":"Bronstein","year":"1992","journal-title":"J Pediatr"},{"issue":"9678","key":"10.1016\/j.jcf.2026.05.014_bib0007","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/S0140-6736(09)60327-5","article-title":"Cystic fibrosis","volume":"373","author":"O'Sullivan","year":"2009","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jcf.2026.05.014_bib0008","doi-asserted-by":"crossref","first-page":"L1117","DOI":"10.1152\/ajplung.00169.2005","article-title":"Rescue of deltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules","volume":"290","author":"Van Goor","year":"2006","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"2","key":"10.1016\/j.jcf.2026.05.014_bib0009","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(16)30427-1","article-title":"Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study","volume":"5","author":"Konstan","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2026.05.014_bib0010","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S1569-1993(14)60019-9","article-title":"The effect of ivacaftor on the rate of lung function decline in CF patients with a G551D-CFTR mutation","volume":"13","author":"Sawicki","year":"2014","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.05.014_bib0011","series-title":"Cystic fibrosis foundation patient registry. 2024 annual data report","year":"2025"},{"key":"10.1016\/j.jcf.2026.05.014_bib0012","series-title":"ECFSPR 2023 annual data report","author":"Zolin","year":"2025"},{"issue":"19","key":"10.1016\/j.jcf.2026.05.014_bib0013","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"10212","key":"10.1016\/j.jcf.2026.05.014_bib0014","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jcf.2026.05.014_bib0015","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A phase 3 open-label study of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2026.05.014_bib0016","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.202411-2231OC","article-title":"Long-term safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in adults and adolescents with cystic fibrosis and at least one f508del allele: a phase 3, open-label extension study","author":"Daines","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2026.05.014_bib0017","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.202502-0512OC","article-title":"Long-term safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in children >\/=6 years with cystic fibrosis and at least one F508del allele: a 192-week, phase 3, open-label extension study","author":"Wainwright","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2026.05.014_bib0018","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.202301-0084OC","article-title":"Phase 3 open-label clinical trial of elexacaftor\/tezacaftor\/ivacaftor in children aged 2 through 5 years with cystic fibrosis and at least one F508del allele","author":"Goralski","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.jcf.2026.05.014_bib0019","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1136\/thoraxjnl-2020-216085","article-title":"Time to get serious about the detection and monitoring of early lung disease in cystic fibrosis","volume":"76","author":"Bayfield","year":"2021","journal-title":"Thorax"},{"issue":"8","key":"10.1016\/j.jcf.2026.05.014_bib0020","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1542\/pir.32.8.325","article-title":"Aggressive behavior in children and adolescents","volume":"32","author":"Zahrt","year":"2011","journal-title":"Pediatr Rev"},{"issue":"4","key":"10.1016\/j.jcf.2026.05.014_bib0021","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ahj.2007.06.008","article-title":"Distribution of creatine kinase in the general population: implications for statin therapy","volume":"154","author":"Brewster","year":"2007","journal-title":"Am Heart J"},{"issue":"33","key":"10.1016\/j.jcf.2026.05.014_bib0022","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004344","article-title":"Creatine kinase in the U.S. population: impact of demographics, comorbidities, and body composition on the normal range","volume":"95","author":"George","year":"2016","journal-title":"Med (Baltim)"},{"issue":"1\u20132","key":"10.1016\/j.jcf.2026.05.014_bib0023","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0009-8981(98)00180-6","article-title":"Distribution of serum creatine kinase activity in young healthy persons","volume":"279","author":"Lev","year":"1999","journal-title":"Clin Chim Acta"},{"issue":"7","key":"10.1016\/j.jcf.2026.05.014_bib0024","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.nmd.2011.04.007","article-title":"Variation of serum creatine kinase (CK) levels and prevalence of persistent hyperCKemia in a Norwegian normal population. The Tromso study","volume":"21","author":"Lilleng","year":"2011","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"10.1016\/j.jcf.2026.05.014_bib0025","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.amjmed.2008.08.033","article-title":"Relationship of ethnic origin, gender, and age to blood creatine kinase levels","volume":"122","author":"Neal","year":"2009","journal-title":"Am J Med"},{"issue":"5","key":"10.1016\/j.jcf.2026.05.014_bib0026","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/ajcp\/79.5.582","article-title":"Heterogeneity of serum creatine kinase activity among racial and gender groups of the population","volume":"79","author":"Wong","year":"1983","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"10.1016\/j.jcf.2026.05.014_bib0027","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S2213-2600(18)30460-0","article-title":"Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study","volume":"7","author":"McNamara","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2026.05.014_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2024.12.006","article-title":"Sweat chloride reflects CFTR function and correlates with clinical outcomes following CFTR modulator treatment","author":"Zemanick","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"S68\u201369","key":"10.1016\/j.jcf.2026.05.014_bib0029","article-title":"Maximizing benefits with early CFTR modulator treatment: lower sweat chllride is associated with improved clinical outcomes in children aged 6 to 11 years [abstract]","volume":"24S2","author":"Linnemann","year":"2025","journal-title":"J Cyst Fibr"},{"issue":"6","key":"10.1016\/j.jcf.2026.05.014_bib0030","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1183\/09031936.00005512","article-title":"Age and height dependence of lung clearance index and functional residual capacity","volume":"41","author":"Lum","year":"2013","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.jcf.2026.05.014_bib0031","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00524-2024","article-title":"Global lung function initiative reference values for multiple breath washout indices","volume":"64","author":"Ramsey","year":"2024","journal-title":"Eur Resp J"},{"issue":"9","key":"10.1016\/j.jcf.2026.05.014_bib0032","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1164\/rccm.201610-2158OC","article-title":"Progression of lung disease in preschool patients with cystic fibrosis","volume":"195","author":"Stanojevic","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1016\/j.jcf.2026.05.014_bib0033","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/j.1651-2227.1997.tb14836.x","article-title":"Failure to thrive: the earliest feature of cystic fibrosis in infants diagnosed by neonatal screening","volume":"86","author":"Giglio","year":"1997","journal-title":"Acta Paediatr"},{"issue":"2","key":"10.1016\/j.jcf.2026.05.014_bib0034","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(15)00545-7","article-title":"Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study","volume":"4","author":"Davies","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.jcf.2026.05.014_bib0035","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1164\/rccm.202008-3177OC","article-title":"Ivacaftor in infants aged 4 to <12 months with cystic fibrosis and a gating mutation. Results of a two-part phase 3 clinical trial","volume":"203","author":"Davies","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1016\/j.jcf.2026.05.014_bib0036","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1164\/rccm.202202-0392OC","article-title":"Efficacy and safety of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis heterozygous for f508del and a minimal function mutation: a phase 3b, randomized, placebo-controlled study","volume":"206","author":"Mall","year":"2022","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326016371?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326016371?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:07:26Z","timestamp":1790107646000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199326016371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1569199326016371"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2026.05.014","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in children \u22652 years with cystic fibrosis: 96-week interim results from a phase 3 open-label extension study","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2026.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}